Valneva Reports FY 2020 Cash of Over €200 Million

Nachrichtenquelle: globenewswire
07.01.2021, 17:45  |  299   |   |   

  • FY 2020 cash and cash equivalents of €204.4 million, exceeding guidance of between €180 million and €200 million1
  • FY 2020 cash and cash equivalents include $130 million from the Lyme disease collaboration with Pfizer2 and €96.7 million from the UK COVID-19 vaccine partnership3
  • No further drawdown from the $85 million debt financing arrangement with leading US funds Deerfield Management Company and OrbiMed4 in H2 2020 ($60 million drawn in H1 2020)

Saint-Herblain (France), January 7, 2021Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today reported preliminary and unaudited cash and cash equivalents of €204.4 million at the end of December 2020, exceeding its guidance of between €180 million and €200 million.

Valneva’s cash and cash equivalents at December 31, 2020 increased to €204.4 million compared to €64.4 million at December 31, 2019. The change was primarily driven by a $130.0 million upfront payment related to the Lyme collaboration agreement with Pfizer, €96.7 million related to the UK COVID-19 vaccine partnership deal, and €48.8 million of net proceeds from the financing arrangement with Deerfield and OrbiMed, offset by €20 million repayments of borrowings to the European Investment Bank. Such amounts are preliminary and unaudited.

Thomas Lingelbach, Chief Executive Officer of Valneva commented, “2020 has been a transformational year for Valneva, marked by the Pfizer and UK government partnerships. With over €200 million of cash, Valneva is in a strong position despite the impact of the COVID-19 pandemic on the travel industry and our commercial travel business. This solid cash position will allow us to focus on the execution of our key programs in 2021.”

Valneva will release its unaudited full-year 2020 financial results on February 25, 2021.

About Valneva SE

Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. The Company has several vaccines in development including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis and DUKORAL indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with over 500 employees. 

Seite 1 von 4


Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Valneva Reports FY 2020 Cash of Over €200 Million FY 2020 cash and cash equivalents of €204.4 million, exceeding guidance of between €180 million and €200 million1FY 2020 cash and cash equivalents include $130 million from the Lyme disease collaboration with Pfizer2 and €96.7 million from the UK …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel